Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002193 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors
A Phase 3 study of HIV Infections, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 3
- Development phase
- 210
- Enrollment target
- 2
- Study locations
NCT00002193: Completed Phase 3 study of HIV Infections, sponsored by Glaxo Wellcome.
NCT00002193 is a Phase 3 study of HIV Infections that has completed, run by Glaxo Wellcome. The registered enrollment target is 210 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (53% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002193, a Phase 3 study of HIV Infections, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 210 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to see if it is safe and effective to add a new protease inhibitor (PI), 141W94, to an anti-HIV regimen that includes 2 nucleoside reverse transcriptase inhibitors (NRTIs).
Conditions Studied
Interventions
- DRUG Amprenavir
Study Locations (2)
Florida
- Children's Diagnostic Treatment Ctr - Fort Lauderdale
Tennessee
- Saint Jude Children's Hosp / Dept of Infect Diseases - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Phase | Phase 3 |
What the finished NCT00002193 record still lists
NCT00002193 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (53% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Amprenavir is the first listed.
NCT00002193 reports a single indexed study location in Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00002193 about?
NCT00002193 is a clinical study titled "Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors". The purpose of this study is to see if it is safe and effective to add a new protease inhibitor (PI), 141W94, to an anti-HIV regimen that includes 2 nucleoside reverse transcriptase inhibitors (NRTIs).
What is the current status of trial NCT00002193?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 210 participants.
What conditions does trial NCT00002193 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002193?
The interventions under investigation include: Amprenavir (DRUG).
Who is sponsoring clinical trial NCT00002193?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002193 being conducted?
This trial has 2 study locations across Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002193's enrollment target sits among peer trials
210 164th of 542 higher than 377 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).